

PERSPECTIVE

Light and inherited retinal degeneration

D M Paskowitz, M M LaVail, J L Duncan

Br J Ophthalmol 2006;**90**:1060–1066. doi: 10.1136/bjo.2006.097436

Light deprivation has long been considered a potential treatment for patients with inherited retinal degenerative diseases, but no therapeutic benefit has been demonstrated to date. In the few clinical studies that have addressed this issue, the underlying mutations were unknown. Our rapidly expanding knowledge of the genes and mechanisms involved in retinal degeneration have made it possible to reconsider the potential value of light restriction in specific genetic contexts. This review summarises the clinical evidence for a modifying role of light exposure in retinal degeneration and experimental evidence from animal models, focusing on retinitis pigmentosa with regional degeneration, Oguchi disease, and Stargardt macular dystrophy. These cases illustrate distinct pathophysiological roles for light, and suggest that light restriction may benefit carefully defined subsets of patients.

However, the underlying genetic defect was not defined for any of the patients in these trials. It is now known that RP exhibits extraordinary genetic heterogeneity (<http://www.sph.uth.tmc.edu/Retnet>), and it remains possible that light deprivation could be beneficial for patients with certain mutations. This idea has received considerable support in recent years from animal studies. For some models of retinal degeneration, the progression of disease is indeed slowed by darkness, accelerated by bright light, or both. Several of these animal models carry mutations also found in patients.

Table 1 lists mammalian animal models of inherited retinal degeneration for which the effects of light have been assessed in peer reviewed studies. For three well characterised groups of models, the animal data are discussed in detail below, together with studies of patients carrying mutations in the corresponding genes. The literature on retinal damage by constant light in wild type albino rodents has been reviewed recently^{5 6} and will not be discussed further. Mutations that cause light dependent retinal degeneration in the fruit fly *Drosophila melanogaster*⁷ are also outside the scope of this paper.

AUTOSOMAL DOMINANT RP: RHODOPSIN MUTATIONS ASSOCIATED WITH REGIONAL DEGENERATION

Rhodopsin (*RHO*) mutations are a common cause of autosomal dominant RP (ADRP), accounting for some 25% of families in the United States.^{76 77} The change of proline to histidine at codon 23 (Pro23His, P23H) is found in the most common American mutant allele.^{35 78} Several mutations including P23H cause a distinctive phenotype classified by Cideciyan and colleagues as class B1.⁷⁹ Typical features include slower progression and better visual function compared to other forms of ADRP; more rapid degeneration in the inferior than in the superior retina, correlating with earlier loss of the superior visual field; and delayed dark adaptation.^{79–90} However, some patients with the P23H mutation have a more uniform distribution of relatively mild degeneration, possibly representing an early stage of disease.⁷⁹

It has been proposed that the faster progression of disease in the inferior retina may result from a modifying effect of light. This argument

It was first suggested over a century ago that light exposure might modify the course of disease in patients with retinal degeneration,¹ implying a possible therapeutic benefit of light deprivation. Four small studies have investigated this hypothesis in patients with retinitis pigmentosa (RP), a group of hereditary retinal dystrophies characterised by progressive photoreceptor degeneration, night blindness, visual field constriction, and electroretinographic (ERG) abnormalities, with rods affected earlier than cones. Berson² used an opaque scleral contact lens to occlude one eye for 6–8 hours per day for 5 years in two young adults with RP. Progression of disease was symmetrical in both patients.² A shorter trial using monocular sunglasses worn by three children with RP for 3 months also showed no protection.¹

A third report described a man with RP who had sustained trauma to the anterior segment of the right eye at age 7, resulting in occlusion of the pupil by a thick membrane. Surgical correction and physiological testing 42 years later revealed that the retina had been protected by a 1.2 log unit filter. Fundus examination and ERG offered no evidence that degeneration had been slowed in the occluded eye.³ In the fourth study, 13 RP patients wore a brown contact lens with low transmission on one eye for 1–3 years. In eight patients, the rate of visual field loss was reported to be slower in the light restricted eye.⁴ However, other measures of visual function were not used, and these data await confirmation.

No benefit of light deprivation has been convincingly demonstrated in patients with RP.

See end of article for authors' affiliations

Correspondence to: Jacque L Duncan, MD, Beckman Vision Center, UCSF School of Medicine, San Francisco, CA 94143-0730, USA; duncanj@vision.ucsf.edu

Accepted for publication 1 May 2006

Table 1 Effects of light exposure on animal models of retinal degeneration

Gene product (symbol)	Mutation	Species	Findings*	Human counterpart†
Modified by light				
Arrestin (<i>Sag</i>)	Knockout ⁸	Mouse	Protection by DR ⁹ Exacerbation by light ^{9, 10} Exacerbation by light ¹⁴	Oguchi disease, ¹¹ ARRP ¹²
ATP/GTP binding protein 1 (<i>Agtbp1</i> , <i>Nna1</i>)	Putative regulatory mutation (<i>pcd1</i>) ¹³	Mouse		Unknown
Crumbs homologue 1 (<i>Crb1</i>)	Knockout ¹⁵	Mouse	Exacerbation by light ¹⁵	LCA, RP12, RPCEV, ¹⁶ PPCA ¹⁷
Mertk (<i>Mertk</i>)	Deletion ¹⁸	Rat	Protection by DR ¹⁹⁻²¹ Exacerbation by light ²¹⁻²³	ARRP ²⁴
Rds/peripherin (<i>Rds</i>)	Insertion ²⁵	Mouse	No protection by DR ²⁶ Exacerbation by light ²⁶	Several forms of retinal dystrophy ²⁷
Rhodopsin (<i>RHO</i>)	Thr4Arg (T4R) ²⁸	Dog	Exacerbation by light ²⁹	ADRP ^{30, 31}
Rhodopsin (<i>Rho</i>)	Val20Gly, Pro23His, Pro27Leu (VPP) ³²	Mouse (tg)	Protection by DR ³³ Exacerbation by light ³⁴	ADRP ³⁵
Rhodopsin (<i>Rho</i>)	Pro23His (P23H) ^{36, 37}	Rat (tg)	Protection by DR ³⁸ Exacerbation by light ³⁸⁻⁴²	ADRP ³⁵
Rhodopsin kinase (<i>Grk1</i> , <i>Rhok</i>)	Knockout ⁴³	Mouse	Protection by DR ⁴³ Exacerbation by light ^{10, 43}	Oguchi disease ⁴⁴
Rim protein (<i>Abca4</i> , <i>Abcr</i>)	Knockout ⁴⁵	Mouse	Prevention of A2E accumulation by DR ⁴⁶	Stargardt disease and other retinal dystrophies ⁴⁷
RPE65 (<i>Rpe65</i>)	Knockout ⁴⁸	Mouse	Protection by DR ⁴⁹ Resistance to light damage ⁵⁰	LCA, early onset severe retinal dystrophy ⁵¹
Solute carrier family 6, taurine transporter (<i>Slc6a6</i> , <i>Tauf</i>)	Knockout ⁵²	Mouse	Protection by DR ⁵³	Unknown
Tubby (<i>Tub</i>)	Splice donor site mutation ^{54, 55}	Mouse	Protection by DR ⁵⁶	ARRP, ^{57, 58} LCA ^{59, ‡}
Unknown	Nervous mutation (<i>nr</i>) ⁶⁰	Mouse	No protection by DR ⁶¹ Exacerbation by light ¹⁴	Unknown
Not modified by light				
Ceroid lipofuscinosis, neuronal 8 (<i>Cln8</i>)	Frameshift ⁶²	Mouse	No protection by DR ⁶³	NCL-8, ⁶² vLINCL ⁶⁴
Microphthalmia associated transcription factor (<i>Mitf</i>)	Asp222Asn (D222N) ⁶⁵	Mouse	No protection by DR ⁶⁶	Waardenburg syndrome type II, ⁶⁷ Tietz syndrome ⁶⁸
Rhodopsin (<i>Rho</i>)	Lys296Glu (K296E) ⁶⁹	Mouse (tg)	No protection by DR ⁶⁹	ADRP ⁷⁰
Rhodopsin (<i>Rho</i>)	Ser334ter ⁷¹	Rat (tg)	No protection by DR ^{38, 72} No exacerbation by light in most experiments ^{38, 41, 73}	ADRP ⁵
Rhodopsin (<i>Rho</i>)	Knockout ⁷⁴	Mouse	Resistance to light damage ⁵⁰	ARRP ⁷⁵

ADRP, autosomal dominant retinitis pigmentosa; ARRP, autosomal recessive retinitis pigmentosa; DR, dark rearing; LCA, Leber congenital amaurosis; NCL, neuronal ceroid lipofuscinosis; PPCA, pigmented paravenous chorioretinal atrophy; RP12, retinitis pigmentosa type 12; RPCEV, retinitis pigmentosa with Coats-like exudative vasculopathy; tg, transgenic; vLINCL, Turkish variant late infantile neuronal ceroid lipofuscinosis.

*"Protection" does not necessarily imply complete rescue. Light exposure protocols vary among studies, but "exacerbation by light" refers to accelerated degeneration in light brighter than that used for routine animal housing in a given study. Because sufficiently bright light can cause retinal damage in wild type animals,⁶ only cases in which exacerbation of degeneration significantly exceeds the damage produced in wild type controls by the same light regimen are included.

†Except where noted, the listed human diseases arise from mutations in genes orthologous to those mutated in the respective animal models. Phenotypes may not correspond precisely. Where more than one human disease is listed, these represent alternative phenotypes arising from mutations in the same gene.

‡These phenotypes are associated with mutations in the human gene *TULP1* (Tubby-like protein 1), which is related to mouse *Tub*, but not orthologous.

§Ser334ter transgenic rats exhibit dominant retinal degeneration, but this mutation has not been reported in human RP.

holds that since most light sources are located in the superior visual field, the inferior retina experiences greater exposure, accelerating the degeneration.^{29, 79, 80, 90-92} Additional clinical evidence for this hypothesis has come from a case series describing two families with the P23H mutation.⁸⁰ In one family, a 28 year old man with an 8 year history of bright light exposure as a lifeguard and ski instructor had more advanced disease than his 52 year old mother. In the other family, one patient had atypical disease, with preferential loss of the inferior visual field and more advanced fundus changes in the superior retina. This patient had served in the navy, and had a history of bright light exposure in the inferior visual field from sunlight reflected from water and welding repairs to flooring.

Studies of three animal models of class B1 RP have demonstrated modification of degeneration by light. "VPP mice" carry a murine opsin transgene with the P23H mutation, together with two other mutations (Val20Gly and Pro27Leu) not known to be pathogenic. Like class B1 patients, they exhibit dominantly inherited retinal degeneration,³² more rapid photoreceptor loss in the inferior retina

when housed with overhead lighting,³³ and delayed dark adaptation.⁹³ Rearing VPP mice in the dark slows, but does not completely prevent, the degeneration. Dark rearing also eliminates the difference between superior and inferior retina, supporting the conclusion that this difference is due to greater light exposure in the inferior retina.³³ A 24 hour exposure to bright light that has no effect on wild type littermates accelerates the degeneration in VPP mice.³⁴

Analysis of rats carrying a murine opsin transgene with the P23H mutation has yielded results similar to those from the VPP mice. Dark rearing slows the rate of degeneration in P23H rats,³⁸ while exposure to bright light accelerates it.³⁸⁻⁴¹ Degeneration is slower in very dim light compared to moderate room light.⁴²

The third animal model offers a particularly dramatic example of the effects of light. A naturally occurring dominant retinal degeneration in English Mastiff dogs is caused by a *RHO* mutation that changes threonine to arginine in the fourth codon (Thr4Arg, T4R).²⁸ This mutant is likely to have properties similar to Thr4Lys (replacing threonine with lysine, which like arginine is positively charged at

physiological pH), a mutation identified in human ADRP with regional degeneration.^{30–31} The T4R dog resembles human class B1 RP in having delayed dark adaptation after bright flashes, and regional photoreceptor loss.²⁸ Cideciyan and colleagues used this large animal model to ask whether light exposure at levels routinely encountered in ophthalmological clinical settings could accelerate the course of disease.²⁹ They found that standard fundus photography in young dogs, before the usual onset of photoreceptor loss in this model, caused rapid and severe degeneration restricted to the photographed areas, with a sharp boundary separating damaged from normal appearing retina. Similar results were obtained with prolonged focal light exposures comparable to indirect ophthalmoscopy, but not with a standard ERG protocol that delivered a much lower light dose.²⁹

The mechanisms of photoreceptor death arising from *RHO* mutations associated with the class B1 phenotype are incompletely understood. When expressed in heterologous cells in culture, the mutant opsins are prone to misfolding and aggregation, regenerate poorly with 11-*cis*-retinal, and are inefficiently transported to the plasma membrane, unlike the wild type protein.^{94–98} P23H is targeted for degradation by the ubiquitin proteasome system, but also impairs this critical pathway, and may interfere with the processing of normal opsin.^{97–98} Photoreceptors may be poorly suited to degrade large amounts of misfolded, mislocalised, or aggregated opsin, because under normal circumstances, most opsin is shed with the outer segment discs and degraded by the retinal pigment epithelium (RPE).⁷⁸ Protein misfolding and aggregation have been implicated in the pathogenesis of several neurodegenerative diseases.⁹⁹

Light could accelerate degeneration through non-specific toxicity to photoreceptors already stressed by the effects of a mutation, or through a specific interaction with mutant rhodopsin. Experiments with cultured photoreceptors have suggested that activation of mislocalised rhodopsin could kill rods by stimulating inappropriate signalling pathways.¹⁰⁰ Mislocalisation has been detected in mice carrying a human P23H opsin transgene^{101–102} and possibly in VPP mice,¹⁰³ but not in P23H rats⁷² or T4R dogs.²⁸ Postmortem analysis of the retina from a patient with the class B1 associated mutation, Thr17Met, did not demonstrate rhodopsin mislocalisation in rods that had not degenerated at the time of death.⁹⁰

Alternatively, mutant rhodopsin may cause abnormalities of phototransduction. ERG analyses of VPP mice and P23H patients have suggested that the lifetime of activated rhodopsin is prolonged, although it could not be determined whether this species represented mutant rhodopsin, the normal protein, or both.^{104–105} Photoexcited rhodopsin triggers the phototransduction cascade by activating transducin. When VPP mice are crossed with knockout mice lacking functional transducin, introducing a genetic block of the cascade, their degeneration in standard cyclic lighting is slowed, supporting a role for phototransduction.¹⁰⁶ A third hypothesis proposes that misfolded opsin destabilises outer segment discs, leading to excessive shedding in response to light, which may contribute to photoreceptor stress and eventual death.¹⁰⁷ Full recovery of rod sensitivity would depend on the slow process of new disc formation, which could explain the greatly prolonged late phase of dark adaptation observed in patients with class B1 RP.⁸⁸ Massive shedding of outer segment tips was observed after retinal photography in T4R dogs, consistent with this hypothesis.²⁹

Whatever the mechanism by which light accelerates degeneration may be, these studies point to two general conclusions. Firstly, until more is known about the effects of light on RP patients with specific mutations, it would be prudent to minimise light exposure during office examinations, fundus photography, and ocular surgery for patients

with the class B1 phenotype.²⁹ The use of hats and sunglasses during regular exposure to bright sunlight may also be advisable. Secondly, this would be a logical population in which to conduct further trials of light restriction.²⁹

OGUCHI DISEASE AND RETINAL DEGENERATION: IMPAIRED RHODOPSIN DEACTIVATION

Following excitation by light, rhodopsin must be rapidly deactivated to restore the rod's full sensitivity. Two proteins are crucial for this process. Rhodopsin kinase (RK) phosphorylates photoactivated rhodopsin at serine and threonine residues near the carboxyl terminus.^{108–109} Arrestin binds to phosphorylated rhodopsin and prevents further activation of transducin.¹¹⁰

Mutations in either RK or arrestin cause Oguchi disease, an autosomal recessive disorder characterised by prolonged insensitivity of rod vision following light exposure.^{11–44–111–112} In the absence of the normal quenching pathway, photoexcited rhodopsin continues to activate transducin until deactivated by a much slower process, possibly regeneration with 11-*cis*-retinal. This persistent activity desensitises the rod, markedly slowing dark adaptation.^{44–113–114} The fundus displays a golden discoloration that disappears with dark adaptation, called the Mizuo-Nakamura phenomenon. Although Oguchi disease is usually described as a form of stationary night blindness, patients with the most common arrestin mutation (1147delA) may also have degenerative features characteristic of RP.^{12–114–117} Phenotypically distinct Oguchi disease and RP may be found in different members of the same family with this mutation,¹¹⁷ or a single patient may have features of both diseases.^{12–115–116} The same mutation has been identified in patients with autosomal recessive RP who had no relatives diagnosed with Oguchi disease.¹² A different arrestin mutation (Arg193ter) has similarly been identified in two siblings with Oguchi disease, one of whom had signs of degeneration while the other did not.¹¹⁸ Therefore, each of these arrestin mutations can produce a spectrum of disease, presumably under the influence of modifying environmental or genetic factors. It remains to be determined whether RK mutations can cause retinal degeneration.¹¹⁹

Rods from knockout mice lacking either RK or arrestin exhibit prolonged photoresponses, consistent with the pathophysiology of Oguchi disease.^{8–43} Photoresponses in RK knockout rods also have greater than normal amplitudes.⁴³ Both strains of knockout mice undergo light dependent photoreceptor degeneration. Under dim cyclic lighting, the only histological abnormality reported in the RK mutant is shortening of rod outer segments. Exposure to brighter light for 24 hours, which does not damage the wild type retina, causes degeneration in RK mutants.⁴³ Similarly, arrestin knockout mice exhibit gradual degeneration in cyclic light, which is greatly accelerated by a constant light regimen that causes no damage in wild type mice.⁹ Mice of both genotypes have normal retinal morphology when dark reared.^{9–43} The prolonged photoresponses of RK and arrestin knockout mice, and the strongly light dependent nature of their degeneration, suggest that excessive activation of the phototransduction cascade causes photoreceptor death in these mutants.^{9–43–120} This conclusion is supported by analysis of double knockout mice lacking RK and transducin, or arrestin and transducin. The transducin mutation largely prevents the degeneration induced by light in the RK and arrestin single knockouts.¹⁰

The animal results suggest that light exposure could be an important modifier of the Oguchi disease phenotype, at least in patients with arrestin mutations. Phototransduction activity is excessive in all patients, but may remain tolerable to photoreceptors in those with moderate light exposure. Those exposed to brighter light over time may be at risk of

degeneration. There is as yet no direct evidence for this hypothesis in patients, but it is consistent with a body of evidence suggesting that constitutive phototransduction can cause either night blindness or retinal degeneration, possibly depending on the degree of transducin activation.^{121 122} For example, three rhodopsin mutations (Gly90Asp, Thr94Ile, and Ala292Glu) cause autosomal dominant congenital night blindness with no reported evidence of degeneration,^{123 124} or with degeneration occurring only later in life.¹²⁵ Biochemical experiments,^{123 126–128} transgenic animal models,^{121 129} and studies of patients¹²⁵ have shown that the mutant opsins activate transducin at low levels even in darkness and desensitise rods, as though they were exposed to a weak background light. In contrast, studies of knockout mice lacking RPE65 suggest that higher levels of constitutive phototransduction can cause degeneration. Loss of RPE65 function disrupts production of 11-*cis*-retinal.^{48 130 131} Therefore, opsin lacks the chromophore and is thought to activate transducin aberrantly, causing rods to behave as if strongly light adapted^{49 132–34} (although this has been disputed).^{135 136} Photoreceptor degeneration in this model is rescued by a transducin null mutation, implicating constitutive phototransduction as its cause.¹³⁴ Human *RPE65* mutations cause severe, early onset retinal dystrophy phenotypes including Leber congenital amaurosis.⁵¹ Light exposure presumably affects the level of abnormal phototransduction in patients with arrestin mutations, and might determine whether their disease manifests as night blindness or degeneration.

Of course, other environmental or genetic factors^{5 50 106 137} might also modulate phototransduction activity, or the vulnerability of photoreceptors, in these patients. However, a report of a patient with Oguchi disease and degeneration preferentially involving the inferior retina,¹¹⁶ similar to the class B1 phenotype of ADRP, hints at a possible role for light. As discussed earlier, this regional predilection could result from increased light exposure in the superior visual field.

STARGARDT DISEASE: TOXIC BYPRODUCTS OF VISION

Stargardt disease (STGD) is a hereditary macular dystrophy whose features often include progressive loss of central vision with onset during the first or second decade of life, macular atrophy, fundus flecks, and a dark choroid on fluorescein angiography.^{138 139} Histopathological changes are most pronounced in and near the macula. These include RPE degeneration and massive accumulation in RPE cells of lipofuscin, believed to consist mainly of non-degradable material derived from ingested photoreceptor outer segments.^{140–142} These findings, together with detailed analysis of fundus and psychophysical abnormalities in patients,¹⁴³ have supported the hypothesis that degeneration of photoreceptors in STGD is secondary to RPE dysfunction and loss. The disease shows autosomal recessive inheritance and is caused by mutations in *ABCA4* (also known as *ABCR*).¹⁴⁴ This gene encodes rim protein (RmP),¹⁴⁵ a transporter localised to the rims of photoreceptor outer segment discs.^{146–148} *ABCA4* mutations have also been identified in fundus flavimaculatus (a variant of STGD),¹⁴⁹ autosomal recessive RP,^{150 151} and cone-rod dystrophy.¹⁵¹ A proposed link to age related macular degeneration^{152 153} is less certain.^{154–156} The clinical phenotype may depend on the degree of residual RmP activity.¹⁵⁷

Insights into the pathogenesis of STGD and its relation to light have come from analysis of knockout mice lacking a functional *Abcr* gene, which exhibit abnormalities of the visual cycle.⁴⁵ During recovery from a photoresponse, activated rhodopsin decays to release all-*trans*-retinal inside the outer segment disc. All-*trans*-retinal reacts with a phospholipid component of the disc membrane to form

N-retinylidene-phosphatidylethanolamine (*N*-ret-PE). RmP translocates *N*-ret-PE from the intradiscal to the outer (cytoplasmic) leaflet of the disc membrane, allowing all-*trans*-retinal to be released, reduced, transported to the RPE, and converted back to 11-*cis*-retinal.^{45 158} In the absence of functional RmP, *N*-ret-PE remains trapped inside the disc, forming further intermediates. When the disc is phagocytosed by the RPE, a final set of reactions converts these to *N*-retinylidene-*N*-retinylethanolamine (A2E),⁴⁶ a component of lipofuscin with several potentially toxic effects on RPE cells.^{159–165} A2E is dramatically elevated in the RPE in both *Abcr* knockout mice⁴⁵ and STGD patients.⁴⁶ The greater lipofuscin accumulation and RPE degeneration in the macula in STGD may be a consequence of the macula's high ratio of photoreceptors to RPE cells.⁴⁵

In this model, A2E is a toxic byproduct of the visual cycle that accumulates to abnormal levels in the RPE of *Abcr* mutant mice and STGD patients as a consequence of rhodopsin activation and retention of *N*-ret-PE within outer segment discs. Therefore, A2E formation should be suppressed by preventing rhodopsin activation. Dark rearing the knockout mice prevents accumulation of A2E, suggesting that light deprivation might slow the progression of STGD and other dystrophies caused by *ABCA4* mutations.⁴⁶

Further studies have suggested an alternative strategy for limiting A2E formation. These began with the observation that some patients taking isotretinoin, a retinoid prescribed for the treatment of severe acne, experience disturbances of night vision.¹⁶⁶ Isotretinoin inhibits the production of 11-*cis*-retinal, interfering with rhodopsin regeneration.^{167 168} Chronic isotretinoin treatment suppresses A2E formation and lipofuscin accumulation in the RPE of *Abcr* mutant mice, presumably by reducing the availability of all-*trans*-retinal to form *N*-ret-PE in photoreceptor outer segments.¹⁶⁹ It remains to be determined whether this or alternative pharmacological approaches^{170–172} can safely and effectively treat patients with STGD or other diseases associated with lipofuscin accumulation.

CONCLUSIONS

Our understanding of the role of light in retinal degeneration continues to evolve through the use of clinical, animal, and in vitro approaches. A growing body of evidence strongly suggests that light exposure can modify the course of at least some retinal dystrophies. This applies particularly to autosomal dominant RP with the class B1 (regional) phenotype, for which marked acceleration by fundus photography has been demonstrated in a large animal model.²⁹ However, carefully designed trials in patients of known genotype are required to confirm hypotheses generated by studies of animal models. Until such results become available, and in the many cases for which the underlying mutations remain unknown, it may be prudent to avoid unnecessary exposure to bright light, especially in clinical settings.

ACKNOWLEDGEMENTS

Supported by the Foundation Fighting Blindness, That Man May See, Inc, the Bernard A Newcomb Macular Degeneration Fund, a Career Development Award from Research to Prevent Blindness (JLD), and by NIH grants EY00415, EY01919, and EY02162.

Authors' affiliations

D M Paskowitz, Medical Scientist Training Program and Beckman Vision Center, UCSF School of Medicine, San Francisco, CA, USA
M M LaVail, J L Duncan, Beckman Vision Center, UCSF School of Medicine, San Francisco, CA, USA

Competing interests: none.

REFERENCES

- 1 **Berson EL.** Light deprivation for early retinitis pigmentosa. A hypothesis. *Arch Ophthalmol* 1971;**85**:521-9.
- 2 **Berson EL.** Light deprivation and retinitis pigmentosa. *Vis Res* 1980;**20**:1179-84.
- 3 **Miyake Y, Sugita S, Horiguchi M, et al.** Light deprivation and retinitis pigmentosa. *Am J Ophthalmol* 1990;**110**:305-6.
- 4 **Stone J, Maslim J, Valter-Kocsi K, et al.** Mechanisms of photoreceptor death and survival in mammalian retina. *Prog Retin Eye Res* 1999;**18**:689-735.
- 5 **Wenzel A, Grimm C, Samaradzija M, et al.** Molecular mechanisms of light-induced photoreceptor apoptosis and neuroprotection for retinal degeneration. *Prog Retin Eye Res* 2005;**24**:275-306.
- 6 **Reme CE.** The dark side of light: rhodopsin and the silent death of vision. The Proctor Lecture. *Invest Ophthalmol Vis Sci* 2005;**46**:2671-82.
- 7 **Kiselev A, Socolich M, Vinos J, et al.** A molecular pathway for light-dependent photoreceptor apoptosis in *Drosophila*. *Neuron* 2000;**28**:139-52.
- 8 **Xu J, Dodd RL, Makino CL, et al.** Prolonged photoresponses in transgenic mouse rods lacking arrestin. *Nature* 1997;**389**:505-9.
- 9 **Chen J, Simon MI, Matthes MT, et al.** Increased susceptibility to light damage in an arrestin knockout mouse model of Oguchi disease (stationary night blindness). *Invest Ophthalmol Vis Sci* 1999;**40**:2978-82.
- 10 **Hao W, Wenzel A, Obin MS, et al.** Evidence for two apoptotic pathways in light-induced retinal degeneration. *Nat Genet* 2002;**32**:254-60.
- 11 **Fuchs S, Nakazawa M, Maw M, et al.** A homozygous 1-base pair deletion in the arrestin gene is a frequent cause of Oguchi disease in Japanese. *Nat Genet* 1995;**10**:360-2.
- 12 **Nakazawa M, Wada Y, Tamai M.** Arrestin gene mutations in autosomal recessive retinitis pigmentosa. *Arch Ophthalmol* 1998;**116**:498-501.
- 13 **Fernandez-Gonzalez A, La Spada AR, Treadaway J, et al.** Purkinje cell degeneration (pcd) phenotypes caused by mutations in the axotomy-induced gene, *Nna1*. *Science* 2002;**295**:1904-6.
- 14 **LaVail MM, Gorris GM, Yasumura D, et al.** Increased susceptibility to constant light in *nr* and *pcd* mice with inherited retinal degenerations. *Invest Ophthalmol Vis Sci* 1999;**40**:1020-4.
- 15 **Van de Pavert SA, Kantardzhieva A, Malysheva A, et al.** Crumbs homologue 1 is required for maintenance of photoreceptor cell polarization and adhesion during light exposure. *J Cell Sci* 2004;**117**:4169-77.
- 16 **den Hollander AI, Davis J, van der Velde-Visser SD, et al.** CRB1 mutation spectrum in inherited retinal dystrophies. *Hum Mutat* 2004;**24**:355-69.
- 17 **McKay GJ, Clarke S, Davis JA, et al.** Pigmented paravenous chorioretinal atrophy is associated with a mutation within the crumbs homolog 1 (CRB1) gene. *Invest Ophthalmol Vis Sci* 2005;**46**:322-8.
- 18 **D'Cruz PM, Yasumura D, Weir J, et al.** Mutation of the receptor tyrosine kinase gene *Mertk* in the retinal dystrophic RCS rat. *Hum Mol Genet* 2000;**9**:645-51.
- 19 **Dowling JE, Sidman RL.** Inherited retinal dystrophy in the rat. *J Cell Biol* 1962;**14**:73-109.
- 20 **LaVail MM, Battelle BA.** Influence of eye pigmentation and light deprivation on inherited retinal dystrophy in the rat. *Exp Eye Res* 1975;**21**:167-92.
- 21 **Kaiz M, Auerbach E.** Retinal degeneration in RCS rats raised under ambient light levels. *Vision Res* 1979;**19**:79-81.
- 22 **Noell WK.** Some animal models of retinitis pigmentosa. *Adv Exp Med Biol* 1977;**77**:87-91.
- 23 **Organisciak DT, Li M, Darrow RM, et al.** Photoreceptor cell damage by light in young Royal College of Surgeons rats. *Curr Eye Res* 1999;**19**:188-96.
- 24 **Gal A, Li Y, Thompson DA, et al.** Mutations in *MERTK*, the human orthologue of the RCS rat retinal dystrophy gene, cause retinitis pigmentosa. *Nat Genet* 2000;**26**:270-1.
- 25 **Ma J, Norton JC, Allen AC, et al.** Retinal degeneration slow (rds) in mouse results from simple insertion of a 1 haplotype-specific element into protein-coding exon II. *Genomics* 1995;**28**:212-9.
- 26 **Sanyal S, Hawkins RK.** Development and degeneration of retina in rds mutant mice: effects of light on the rate of degeneration in albino and pigmented homozygous and heterozygous mutant and normal mice. *Vis Res* 1986;**26**:1177-85.
- 27 OMIM 179605, <http://www.ncbi.nlm.nih.gov/Omim>.
- 28 **Kijas JW, Cideciyan AV, Aleman TS, et al.** Naturally occurring rhodopsin mutation in the dog causes retinal dysfunction and degeneration mimicking human dominant retinitis pigmentosa. *Proc Natl Acad Sci USA* 2002;**99**:6328-33.
- 29 **Cideciyan AV, Jacobson SG, Aleman TS, et al.** In vivo dynamics of retinal injury and repair in the rhodopsin mutant dog model of human retinitis pigmentosa. *Proc Natl Acad Sci USA* 2005;**102**:5233-8.
- 30 **Bunge S, Wedemann H, David D, et al.** Molecular analysis and genetic mapping of the rhodopsin gene in families with autosomal dominant retinitis pigmentosa. *Genomics* 1993;**17**:230-3.
- 31 **Van den Born LI, van Schooneveld MJ, de Jong LA, et al.** Thr4Lys rhodopsin mutation is associated with autosomal dominant retinitis pigmentosa of the cone-rod type in a small Dutch family. *Ophthalmic Genet* 1994;**15**:51-60.
- 32 **Naash MI, Hollyfield JG, al-Ubaidi MR, et al.** Simulation of human autosomal dominant retinitis pigmentosa in transgenic mice expressing a mutated murine opsin gene. *Proc Natl Acad Sci USA* 1993;**90**:5499-503.
- 33 **Naash MI, Peachey NS, Li ZY, et al.** Light-induced acceleration of photoreceptor degeneration in transgenic mice expressing mutant rhodopsin. *Invest Ophthalmol Vis Sci* 1996;**37**:775-82.
- 34 **Wang M, Lam TT, Tso MO, et al.** Expression of a mutant opsin gene increases the susceptibility of the retina to light damage. *Vis Neurosci* 1997;**14**:55-62.
- 35 **Dryja TP, McGee TL, Reichel E, et al.** A point mutation of the rhodopsin gene in one form of retinitis pigmentosa. *Nature* 1990;**343**:364-6.
- 36 **Lewin AS, Drenser KA, Hauswirth WW, et al.** Ribozyme rescue of photoreceptor cells in a transgenic rat model of autosomal dominant retinitis pigmentosa. *Nat Med* 1998;**4**:967-71.
- 37 **Machida S, Kondo M, Jamison JA, et al.** P23H rhodopsin transgenic rat: correlation of retinal function with histopathology. *Invest Ophthalmol Vis Sci* 2000;**41**:3200-9.
- 38 **Organisciak DT, Darrow RM, Barsalou L, et al.** Susceptibility to retinal light damage in transgenic rats with rhodopsin mutations. *Invest Ophthalmol Vis Sci* 2003;**44**:486-92.
- 39 **Nir I, Harrison JM, Liu C, et al.** Extended photoreceptor viability by light stress in the RCS rats but not in the opsin P23H mutant rats. *Invest Ophthalmol Vis Sci* 2001;**42**:842-9.
- 40 **Bicknell IR, Darrow R, Barsalou L, et al.** Alterations in retinal rod outer segment fatty acids and light-damage susceptibility in P23H rats. *Mol Vis* 2002;**8**:333-40.
- 41 **Vaughan DK, Coulibaly SF, Darrow RM, et al.** A morphometric study of light-induced damage in transgenic rat models of retinitis pigmentosa. *Invest Ophthalmol Vis Sci* 2003;**44**:848-55.
- 42 **Walsh N, van Driel D, Lee D, et al.** Multiple vulnerability of photoreceptors to mesopic ambient light in the P23H transgenic rat. *Brain Res* 2004;**1013**:194-203.
- 43 **Chen CK, Burns ME, Spencer M, et al.** Abnormal photoresponses and light-induced apoptosis in rods lacking rhodopsin kinase. *Proc Natl Acad Sci USA* 1999;**96**:3718-22.
- 44 **Yamamoto S, Sippel KC, Berson EL, et al.** Defects in the rhodopsin kinase gene in the Oguchi form of stationary night blindness. *Nat Genet* 1997;**15**:175-8.
- 45 **Weng J, Mata NL, Azarian SM, et al.** Insights into the function of Rim protein in photoreceptors and etiology of Stargardt's disease from the phenotype in *abc* knockout mice. *Cell* 1999;**98**:13-23.
- 46 **Mata NL, Weng J, Travis GH.** Biosynthesis of a major lipofuscin fluorophore in mice and humans with ABCR-mediated retinal and macular degeneration. *Proc Natl Acad Sci USA* 2000;**97**:7154-9.
- 47 OMIM 601691, <http://www.ncbi.nlm.nih.gov/Omim>.
- 48 **Redmond TM, Yu S, Lee E, et al.** Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle. *Nat Genet* 1998;**20**:344-51.
- 49 **Fan J, Woodruff ML, Cilluffo MC, et al.** Opsin activation of transduction in the rods of dark-reared Rpe65 knockout mice. *J Physiol* 2005;**568**:83-95.
- 50 **Grimm C, Wenzel A, Hafezi F, et al.** Protection of Rpe65-deficient mice identifies rhodopsin as a mediator of light-induced retinal degeneration. *Nat Genet* 2000;**25**:63-6.
- 51 **Thompson DA, Gal A.** Vitamin A metabolism in the retinal pigment epithelium: genes, mutations, and diseases. *Prog Retin Eye Res* 2003;**22**:683-703.
- 52 **Heller-Stilb B, van Roeyen C, Rascher K, et al.** Disruption of the taurine transporter gene (*taut*) leads to retinal degeneration in mice. *FASEB J* 2002;**16**:231-3.
- 53 **Rascher K, Servos G, Berthold G, et al.** Light deprivation slows but does not prevent the loss of photoreceptors in taurine transporter knockout mice. *Vis Res* 2004;**44**:2091-100.
- 54 **Noben-Trauth K, Naggert JK, North MA, et al.** A candidate gene for the mouse mutation *tubby*. *Nature* 1996;**380**:534-8.
- 55 **Kleyn PW, Fan W, Kovats SG, et al.** Identification and characterization of the mouse obesity gene *tubby*: a member of a novel gene family. *Cell* 1996;**85**:281-90.
- 56 **Kong L, Li F, Soleman CE, et al.** Bright cyclic light accelerates photoreceptor cell degeneration in *tubby* mice. *Neurobiol Dis* 2005;(in press).
- 57 **Hagstrom SA, North MA, Nishina PL, et al.** Recessive mutations in the gene encoding the *tubby*-like protein TULP1 in patients with retinitis pigmentosa. *Nat Genet* 1998;**18**:174-6.
- 58 **Banerjee P, Kleyn PW, Knowles JA, et al.** TULP1 mutation in two extended Dominican kindreds with autosomal recessive retinitis pigmentosa. *Nat Genet* 1998;**18**:177-9.
- 59 **Hanein S, Perrault I, Gerber S, et al.** Leber congenital amaurosis: comprehensive survey of the genetic heterogeneity, refinement of the clinical definition, and genotype-phenotype correlations as a strategy for molecular diagnosis. *Hum Mutat* 2004;**23**:306-17.
- 60 **Mullen RJ, LaVail MM.** Two types of retinal degeneration in cerebellar mutant mice. *Nature* 1975;**258**:528-30.
- 61 **LaVail MM.** Interaction of environmental light and eye pigmentation with inherited retinal degenerations. *Vis Res* 1980;**20**:1173-7.
- 62 **Ranta S, Zhang Y, Ross B, et al.** The neuronal ceroid lipofuscinoses in human EPMR and *mnd* mutant mice are associated with mutations in *CLN8*. *Nat Genet* 1999;**23**:233-6.
- 63 **Messer A, Plummer J, MacMillen MC, et al.** Genetics of primary and timing effects in the *mnd* mouse. *Am J Med Genet* 1995;**57**:361-4.
- 64 **Ranta S, Topcu M, Tegelberg S, et al.** Variant late infantile neuronal ceroid lipofuscinosis in a subset of Turkish patients is allelic to Northern epilepsy. *Hum Mutat* 2004;**23**:300-5.
- 65 **Steingrimsson E, Moore KJ, Lamoreux ML, et al.** Molecular basis of mouse microphthalmia (*mi*) mutations helps explain their developmental and phenotypic consequences. *Nat Genet* 1994;**8**:256-63.
- 66 **Smith SB, Cope BK, McCoy JR.** Effects of dark-rearing on the retinal degeneration of the C57BL/6-mivit/mivit mouse. *Exp Eye Res* 1994;**58**:77-84.
- 67 **Tassabehji M, Newton VE, Read AP.** Waardenburg syndrome type 2 caused by mutations in the human microphthalmia (*MITF*) gene. *Nat Genet* 1994;**8**:251-5.

- 68 **Smith SD**, Kelley PM, Kenyon JB, *et al*. Tietz syndrome (hypopigmentation/deafness) caused by mutation of MITF. *J Med Genet* 2000;**37**:446–8.
- 69 **Li T**, Franson WK, Gordon JW, *et al*. Constitutive activation of phototransduction by K296E opsin is not a cause of photoreceptor degeneration. *Proc Natl Acad Sci USA* 1995;**92**:3551–5.
- 70 **Keen TJ**, Inglehearn CF, Lester DH, *et al*. Autosomal dominant retinitis pigmentosa: four new mutations in rhodopsin, one of them in the retinal attachment site. *Genomics* 1991;**11**:199–205.
- 71 **Liu C**, Li Y, Peng M, *et al*. Activation of caspase-3 in the retina of transgenic rats with the rhodopsin mutation S334ter during photoreceptor degeneration. *J Neurosci* 1999;**19**:4778–85.
- 72 **Green ES**, Menz MD, LaVail MM, *et al*. Characterization of rhodopsin mis-sorting and constitutive activation in a transgenic rat model of retinitis pigmentosa. *Invest Ophthalmol Vis Sci* 2000;**41**:1546–53.
- 73 **Ranchon I**, LaVail MM, Kotake Y, *et al*. Free radical trap phenyl-N-tert-butyl nitron protects against light damage but does not rescue P23H and S334ter rhodopsin transgenic rats from inherited retinal degeneration. *J Neurosci* 2003;**23**:6050–7.
- 74 **Humphries MM**, Rancourt D, Farrar GJ, *et al*. Retinopathy induced in mice by targeted disruption of the rhodopsin gene. *Nat Genet* 1997;**15**:216–19.
- 75 **Rosenfeld PJ**, Cowley GS, McGee TL, *et al*. A null mutation in the rhodopsin gene causes rod photoreceptor dysfunction and autosomal recessive retinitis pigmentosa. *Nat Genet* 1992;**1**:209–13.
- 76 **Sung CH**, Davenport CM, Hennessey JC, *et al*. Rhodopsin mutations in autosomal dominant retinitis pigmentosa. *Proc Natl Acad Sci USA* 1991;**88**:6481–5.
- 77 **Dryja TP**, McEvoy JA, McGee TL, *et al*. Novel rhodopsin mutations Gly114Val and Gln184Pro in dominant retinitis pigmentosa. *Invest Ophthalmol Vis Sci* 2000;**41**:3124–7.
- 78 **Dryja TP**, Hahn LB, Cowley GS, *et al*. Mutation spectrum of the rhodopsin gene among patients with autosomal dominant retinitis pigmentosa. *Proc Natl Acad Sci USA* 1991;**88**:9370–4.
- 79 **Cideciyan AV**, Hood DC, Huang Y, *et al*. Disease sequence from mutant rhodopsin allele to rod and cone photoreceptor degeneration in man. *Proc Natl Acad Sci USA* 1998;**95**:7103–8.
- 80 **Heckenlively JR**, Rodriguez JA, Daiger SP. Autosomal dominant sectoral retinitis pigmentosa. Two families with transversion mutation in codon 23 of rhodopsin. *Arch Ophthalmol* 1991;**109**:84–91.
- 81 **Berson EL**, Rosner B, Sandberg MA, *et al*. Ocular findings in patients with autosomal dominant retinitis pigmentosa and a rhodopsin gene defect (Pro-23-His). *Arch Ophthalmol* 1991;**109**:92–101.
- 82 **Jacobson SG**, Kemp CM, Sung CH, *et al*. Retinal function and rhodopsin levels in autosomal dominant retinitis pigmentosa with rhodopsin mutations. *Am J Ophthalmol* 1991;**112**:256–71.
- 83 **Fishman GA**, Stone EM, Gilbert LD, *et al*. Ocular findings associated with a rhodopsin gene codon 58 transversion mutation in autosomal dominant retinitis pigmentosa. *Arch Ophthalmol* 1991;**109**:1387–93.
- 84 **Stone EM**, Kimura AE, Nichols BE, *et al*. Regional distribution of retinal degeneration in patients with the proline to histidine mutation in codon 23 of the rhodopsin gene. *Ophthalmology* 1991;**98**:1806–13.
- 85 **Fishman GA**, Stone EM, Sheffield VC, *et al*. Ocular findings associated with rhodopsin gene codon 17 and codon 182 transition mutations in dominant retinitis pigmentosa. *Arch Ophthalmol* 1992;**110**:54–62.
- 86 **Kemp CM**, Jacobson SG, Roman AJ, *et al*. Abnormal rod dark adaptation in autosomal dominant retinitis pigmentosa with proline-23-histidine rhodopsin mutation. *Am J Ophthalmol* 1992;**113**:165–74.
- 87 **Fishman GA**, Stone EM, Gilbert LD, *et al*. Ocular findings associated with a rhodopsin gene codon 106 mutation. Glycine-to-arginine change in autosomal dominant retinitis pigmentosa. *Arch Ophthalmol* 1992;**110**:646–53.
- 88 **Moore AT**, Fitzke FW, Kemp CM, *et al*. Abnormal dark adaptation kinetics in autosomal dominant sector retinitis pigmentosa due to rod opsin mutation. *Br J Ophthalmol* 1992;**76**:465–9.
- 89 **Hayakawa M**, Hotta Y, Imai Y, *et al*. Clinical features of autosomal dominant retinitis pigmentosa with rhodopsin gene codon 17 mutation and retinal neovascularization in a Japanese patient. *Am J Ophthalmol* 1993;**115**:168–73.
- 90 **Li ZY**, Jacobson SG, Milam AH. Autosomal dominant retinitis pigmentosa caused by the threonine-17-methionine rhodopsin mutation: retinal histopathology and immunocytochemistry. *Exp Eye Res* 1994;**58**:397–408.
- 91 **Adrian W**, Everson RW, Schmidt I. Protection against photic damage in retinitis pigmentosa. *Adv Exp Med Biol* 1977;**77**:233–47.
- 92 **Schwartz L**, Boelle PY, D'Hermies F, *et al*. Blue light dose distribution and retinitis pigmentosa visual field defects: an hypothesis. *Med Hypotheses* 2003;**60**:644–9.
- 93 **Goto Y**, Peachey NS, Ripps H, *et al*. Functional abnormalities in transgenic mice expressing a mutant rhodopsin gene. *Invest Ophthalmol Vis Sci* 1995;**36**:62–71.
- 94 **Sung CH**, Schneider BG, Agarwal N, *et al*. Functional heterogeneity of mutant rhodopsins responsible for autosomal dominant retinitis pigmentosa. *Proc Natl Acad Sci USA* 1991;**88**:8840–4.
- 95 **Kaushal S**, Khorana HG. Structure and function in rhodopsin. 7. Point mutations associated with autosomal dominant retinitis pigmentosa. *Biochemistry* 1994;**33**:6121–8.
- 96 **Liu X**, Garriga P, Khorana HG. Structure and function in rhodopsin: correct folding and misfolding in two point mutants in the intradiscal domain of rhodopsin identified in retinitis pigmentosa. *Proc Natl Acad Sci USA* 1996;**93**:4554–9.
- 97 **Saliba RS**, Munro PM, Luthert PJ, *et al*. The cellular fate of mutant rhodopsin: quality control, degradation and aggresome formation. *J Cell Sci* 2002;**115**:2907–18.
- 98 **Iling ME**, Rajan RS, Bence NF, *et al*. A rhodopsin mutant linked to autosomal dominant retinitis pigmentosa is prone to aggregate and interacts with the ubiquitin proteasome system. *J Biol Chem* 2002;**277**:34150–60.
- 99 **Ross CA**, Poirier MA. Protein aggregation and neurodegenerative disease. *Nat Med* 2004;**10**(Suppl):S10–7.
- 100 **Alfinito PD**, Townes-Anderson E. Activation of mislocalized opsin kills rod cells: a novel mechanism for rod cell death in retinal disease. *Proc Natl Acad Sci USA* 2002;**99**:5655–60.
- 101 **Olsson JE**, Gordon JW, Pawlyk BS, *et al*. Transgenic mice with a rhodopsin mutation (Pro23His): a mouse model of autosomal dominant retinitis pigmentosa. *Neuron* 1992;**9**:815–30.
- 102 **Roof DJ**, Adamian M, Hayes A. Rhodopsin accumulation at abnormal sites in retinas of mice with a human P23H rhodopsin transgene. *Invest Ophthalmol Vis Sci* 1994;**35**:4049–62.
- 103 **Wu TH**, Ting TD, Okajima TI, *et al*. Opsin localization and rhodopsin photochemistry in a transgenic mouse model of retinitis pigmentosa. *Neuroscience* 1998;**87**:709–17.
- 104 **Birch DG**, Hood DC, Nusinowitz S, *et al*. Abnormal activation and inactivation mechanisms of rod transduction in patients with autosomal dominant retinitis pigmentosa and the pro-23-his mutation. *Invest Ophthalmol Vis Sci* 1995;**36**:1603–14.
- 105 **Goto Y**, Peachey NS, Zirolu NE, *et al*. Rod phototransduction in transgenic mice expressing a mutant opsin gene. *J Opt Soc Am A Opt Image Sci Vis* 1996;**13**:577–85.
- 106 **Samardzija M**, Wenzel A, Naash M, *et al*. Rpe65 as a modifier gene for inherited retinal degeneration. *Eur J Neurosci* 2006;**23**:1028–34.
- 107 **Berson EL**. Retinitis pigmentosa: unfolding its mystery. *Proc Natl Acad Sci USA* 1996;**93**:4526–8.
- 108 **Mendez A**, Burns ME, Roca A, *et al*. Rapid and reproducible deactivation of rhodopsin requires multiple phosphorylation sites. *Neuron* 2000;**28**:153–64.
- 109 **Maeda T**, Imanishi Y, Palczewski K. Rhodopsin phosphorylation: 30 years later. *Prog Retin Eye Res* 2003;**22**:417–34.
- 110 **Wilden U**, Hall SW, Kuhn H. Phosphodiesterase activation by photoexcited rhodopsin is quenched when rhodopsin is phosphorylated and binds the intrinsic 48-kDa protein of rod outer segments. *Proc Natl Acad Sci USA* 1986;**83**:1174–8.
- 111 **Khani SC**, Nielsen L, Vogt TM. Biochemical evidence for pathogenicity of rhodopsin kinase mutations correlated with the Oguchi form of congenital stationary night blindness. *Proc Natl Acad Sci USA* 1998;**95**:2824–7.
- 112 **Nakamura M**, Yamamoto S, Okada M, *et al*. Novel mutations in the arrestin gene and associated clinical features in Japanese patients with Oguchi's disease. *Ophthalmology* 2004;**111**:1410–14.
- 113 **Cideciyan AV**, Zhao X, Nielsen L, *et al*. Null mutation in the rhodopsin kinase gene slows recovery kinetics of rod and cone phototransduction in man. *Proc Natl Acad Sci USA* 1998;**95**:328–33.
- 114 **Dryja TP**. Molecular genetics of Oguchi disease, fundus albipunctatus, and other forms of stationary night blindness: LVII Edward Jackson Memorial Lecture. *Am J Ophthalmol* 2000;**130**:547–63.
- 115 **Nakazawa M**, Wada Y, Fuchs S, *et al*. Oguchi disease: phenotypic characteristics of patients with the frequent 1147delA mutation in the arrestin gene. *Retina* 1997;**17**:17–22.
- 116 **Nakamachi Y**, Nakamura M, Fujii S, *et al*. Oguchi disease with sectoral retinitis pigmentosa harboring adenine deletion at position 1147 in the arrestin gene. *Am J Ophthalmol* 1998;**125**:249–51.
- 117 **Yoshii M**, Murakami A, Akeo K, *et al*. Visual function and gene analysis in a family with Oguchi's disease. *Ophthalmic Res* 1998;**30**:394–401.
- 118 **Maw M**, Kumaramanickavel G, Kar B, *et al*. Two Indian siblings with Oguchi disease are homozygous for an arrestin mutation encoding premature termination. *Hum Mutat* 1998;**1**:S317–9.
- 119 **Yamamoto S**, Khani SC, Berson EL, *et al*. Evaluation of the rhodopsin kinase gene in patients with retinitis pigmentosa. *Exp Eye Res* 1997;**65**:249–53.
- 120 **Fain GL**, Lisman JE. Light, Ca²⁺, and photoreceptor death: new evidence for the equivalent-light hypothesis from arrestin knockout mice. *Invest Ophthalmol Vis Sci* 1999;**40**:2770–2.
- 121 **Sieving PA**, Fowler ML, Bush RA, *et al*. Constitutive "light" adaptation in rods from G90D rhodopsin: a mechanism for human congenital night blindness without rod cell loss. *J Neurosci* 2001;**21**:5449–60.
- 122 **Lem J**, Fain GL. Constitutive opsin signaling: night blindness or retinal degeneration? *Trends Mol Med* 2004;**10**:150–7.
- 123 **Dryja TP**, Berson EL, Rao VR, *et al*. Heterozygous missense mutation in the rhodopsin gene as a cause of congenital stationary night blindness. *Nat Genet* 1993;**4**:280–3.
- 124 **al-Jandal N**, Farrar GJ, Kiang AS, *et al*. A novel mutation within the rhodopsin gene (Thr-94-Ile) causing autosomal dominant congenital stationary night blindness. *Hum Mutat* 1999;**13**:75–81.
- 125 **Sieving PA**, Richards JE, Naarendorp F, *et al*. Dark-light: model for night blindness from the human rhodopsin Gly-90->Asp mutation. *Proc Natl Acad Sci USA* 1995;**92**:880–4.
- 126 **Rao VR**, Cohen GB, Oprian DD. Rhodopsin mutation G90D and a molecular mechanism for congenital night blindness. *Nature* 1994;**367**:639–42.
- 127 **Ramon E**, del Valle LJ, Garriga P. Unusual thermal and conformational properties of the rhodopsin congenital night blindness mutant Thr-94->Ile. *J Biol Chem* 2003;**278**:6427–32.
- 128 **Gross AK**, Rao VR, Oprian DD. Characterization of rhodopsin congenital night blindness mutant T94I. *Biochemistry* 2003;**42**:2009–15.
- 129 **Jin S**, Cornwall MC, Oprian DD. Opsin activation as a cause of congenital night blindness. *Nat Neurosci* 2003;**6**:731–5.
- 130 **Jin M**, Li S, Moghrabi WN, *et al*. Rpe65 is the retinoid isomerase in bovine retinal pigment epithelium. *Cell* 2005;**122**:449–59.

- 131 **Moiseyev G**, Chen Y, Takahashi Y, *et al*. RPE65 is the isomerohydrolase in the retinoid visual cycle. *Proc Natl Acad Sci USA* 2005;**102**:12413–18.
- 132 **Melia TJ Jr**, Cowan CW, Angleson JK, *et al*. A comparison of the efficiency of G protein activation by ligand-free and light-activated forms of rhodopsin. *Biophys J* 1997;**73**:3182–91.
- 133 **Van Hooser JP**, Liang Y, Maeda T, *et al*. Recovery of visual functions in a mouse model of Leber congenital amaurosis. *J Biol Chem* 2002;**277**:19173–82.
- 134 **Woodruff ML**, Wang Z, Chung HY, *et al*. Spontaneous activity of opsin apoprotein is a cause of Leber congenital amaurosis. *Nat Genet* 2003;**35**:158–64.
- 135 **Ablonczy Z**, Crouch RK, Goletz PW, *et al*. 11-cis-retinal reduces constitutive opsin phosphorylation and improves quantum catch in retinoid-deficient mouse rod photoreceptors. *J Biol Chem* 2002;**277**:40491–8.
- 136 **Aleman TS**, Jacobson SG, Chico JD, *et al*. Impairment of the transient pupillary light reflex in Rpe65(-/-) mice and humans with leber congenital amaurosis. *Invest Ophthalmol Vis Sci* 2004;**45**:1259–71.
- 137 **Danciger M**, Matthes MT, Yasamura D, *et al*. A QTL on distal chromosome 3 that influences the severity of light-induced damage to mouse photoreceptors. *Mamm Genome* 2000;**11**:422–7.
- 138 **Stargardt K**. Ueber familiare, progressive degeneration in der maculagegend des auges. *Graefes Arch Ophthalmol* 1909;**71**:534–50.
- 139 **Fishman GA**, Stone EM, Grover S, *et al*. Variation of clinical expression in patients with Stargardt dystrophy and sequence variations in the ABCR gene. *Arch Ophthalmol* 1999;**117**:504–10.
- 140 **Eagle RC Jr**, Lucier AC, Bernardino VB Jr, *et al*. Retinal pigment epithelial abnormalities in fundus flavimaculatus: a light and electron microscopic study. *Ophthalmology* 1980;**87**:1189–200.
- 141 **Birnbach CD**, Jarvelainen M, Possin DE, *et al*. Histopathology and immunocytochemistry of the neurosensory retina in fundus flavimaculatus. *Ophthalmology* 1994;**101**:1211–9.
- 142 **Sparrow JR**, Boulton M. RPE lipofuscin and its role in retinal pathobiology. *Exp Eye Res* 2005;**80**:595–606.
- 143 **Cideciyan AV**, Aleman TS, Swider M, *et al*. Mutations in ABCA4 result in accumulation of lipofuscin before slowing of the retinoid cycle: a reappraisal of the human disease sequence. *Hum Mol Genet* 2004;**13**:525–34.
- 144 **Allikmets R**, Singh N, Sun H, *et al*. A photoreceptor cell-specific ATP-binding transporter gene (ABCR) is mutated in recessive Stargardt macular dystrophy. *Nat Genet* 1997;**15**:236–46.
- 145 **Azarian SM**, Travis GH. The photoreceptor rim protein is an ABC transporter encoded by the gene for recessive Stargardt's disease (ABCR). *FEBS Lett* 1997;**409**:247–52.
- 146 **Illing M**, Molday LL, Molday RS. The 220-kDa rim protein of retinal rod outer segments is a member of the ABC transporter superfamily. *J Biol Chem* 1997;**272**:10303–10.
- 147 **Sun H**, Nathans J. Stargardt's ABCR is localized to the disc membrane of retinal rod outer segments. *Nat Genet* 1997;**17**:15–16.
- 148 **Molday LL**, Rabin AR, Molday RS. ABCR expression in foveal cone photoreceptors and its role in Stargardt macular dystrophy. *Nat Genet* 2000;**25**:257–8.
- 149 **Rozet JM**, Gerber S, Souied E, *et al*. Spectrum of ABCR gene mutations in autosomal recessive macular dystrophies. *Eur J Hum Genet* 1998;**6**:291–5.
- 150 **Martinez-Mir A**, Paloma E, Allikmets R, *et al*. Retinitis pigmentosa caused by a homozygous mutation in the Stargardt disease gene ABCR. *Nat Genet* 1998;**18**:11–12.
- 151 **Cremers FP**, van de Pol DJ, van Driel M, *et al*. Autosomal recessive retinitis pigmentosa and cone-rod dystrophy caused by splice site mutations in the Stargardt's disease gene ABCR. *Hum Mol Genet* 1998;**7**:355–62.
- 152 **Allikmets R**, Shroyer NF, Singh N, *et al*. Mutation of the Stargardt disease gene (ABCR) in age-related macular degeneration. *Science* 1997;**277**:1805–7.
- 153 **Mata NL**, Tzekov RT, Liu X, *et al*. Delayed dark-adaptation and lipofuscin accumulation in abcr+/- mice: implications for involvement of ABCR in age-related macular degeneration. *Invest Ophthalmol Vis Sci* 2001;**42**:1685–90.
- 154 **Stone EM**, Webster AR, Vandenburgh K, *et al*. Allelic variation in ABCR associated with Stargardt disease but not age-related macular degeneration. *Nat Genet* 1998;**20**:328–9.
- 155 **Guymer RH**, Heon E, Lotery AJ, *et al*. Variation of codons 1961 and 2177 of the Stargardt disease gene is not associated with age-related macular degeneration. *Arch Ophthalmol* 2001;**119**:745–51.
- 156 **Schmidt S**, Postel EA, Agarwal A, *et al*. Detailed analysis of allelic variation in the ABCA4 gene in age-related maculopathy. *Invest Ophthalmol Vis Sci* 2003;**44**:2868–75.
- 157 **van Driel MA**, Maugeri A, Klevering BJ, *et al*. ABCR unites what ophthalmologists divide(s). *Ophthalmic Genet* 1998;**19**:117–22.
- 158 **Beharry S**, Zhong M, Molday RS. N-retinylidene-phosphatidylethanolamine is the preferred retinoid substrate for the photoreceptor-specific ABC transporter ABCA4 (ABCR). *J Biol Chem* 2004;**279**:53972–9.
- 159 **Eldred GE**, Lasky MR. Retinal age pigments generated by self-assembling lysosomotropic detergents. *Nature* 1993;**361**:724–6.
- 160 **Holz FG**, Schutt F, Kopitz J, *et al*. Inhibition of lysosomal degradative functions in RPE cells by a retinoid component of lipofuscin. *Invest Ophthalmol Vis Sci* 1999;**40**:737–43.
- 161 **Sparrow JR**, Parish CA, Hashimoto M, *et al*. A2E, a lipofuscin fluorophore, in human retinal pigmented epithelial cells in culture. *Invest Ophthalmol Vis Sci* 1999;**40**:2988–95.
- 162 **Sparrow JR**, Nakanishi K, Parish CA. The lipofuscin fluorophore A2E mediates blue light-induced damage to retinal pigmented epithelial cells. *Invest Ophthalmol Vis Sci* 2000;**41**:1981–9.
- 163 **Suter M**, Reme C, Grimm C, *et al*. Age-related macular degeneration. The lipofuscin component N-retinyl-N-retinylidene ethanolamine detaches proapoptotic proteins from mitochondria and induces apoptosis in mammalian retinal pigment epithelial cells. *J Biol Chem* 2000;**275**:39625–30.
- 164 **Finnemann SC**, Leung LW, Rodriguez-Boulan E. The lipofuscin component A2E selectively inhibits phagolysosomal degradation of photoreceptor phospholipid by the retinal pigment epithelium. *Proc Natl Acad Sci USA* 2002;**99**:3842–7.
- 165 **Sparrow JR**, Fishkin N, Zhou J, *et al*. A2E, a byproduct of the visual cycle. *Vis Res* 2003;**43**:2983–90.
- 166 **Weleber RG**, Denman ST, Hanifin JM, *et al*. Abnormal retinal function associated with isotretinoin therapy for acne. *Arch Ophthalmol* 1986;**104**:831–7.
- 167 **Law WC**, Rando RR. The molecular basis of retinoic acid induced night blindness. *Biochem Biophys Res Commun* 1989;**161**:825–9.
- 168 **Sieving PA**, Chaudhry P, Kondo M, *et al*. Inhibition of the visual cycle in vivo by 13-cis retinoic acid protects from light damage and provides a mechanism for night blindness in isotretinoin therapy. *Proc Natl Acad Sci USA* 2001;**98**:1835–40.
- 169 **Radu RA**, Mata NL, Nusinowitz S, *et al*. Treatment with isotretinoin inhibits lipofuscin accumulation in a mouse model of recessive Stargardt's macular degeneration. *Proc Natl Acad Sci USA* 2003;**100**:4742–7.
- 170 **Golczak M**, Kuksa V, Maeda T, *et al*. Positively charged retinoids are potent and selective inhibitors of the trans-cis isomerization in the retinoid (visual) cycle. *Proc Natl Acad Sci USA* 2005;**102**:8162–7.
- 171 **Radu RA**, Han Y, Bui TV, *et al*. Reductions in serum vitamin A arrest accumulation of toxic retinal fluorophores: a potential therapy for treatment of lipofuscin-based retinal diseases. *Invest Ophthalmol Vis Sci* 2005;**46**:4393–401.
- 172 **Maiti P**, Kong J, Kim SR, *et al*. Small molecule RPE65 antagonists limit the visual cycle and prevent lipofuscin formation. *Biochemistry* 2006;**45**:852–60.



Light and inherited retinal degeneration

D M Paskowitz, M M LaVail and J L Duncan

Br J Ophthalmol 2006 90: 1060-1066 originally published online May 17, 2006

doi: 10.1136/bjo.2006.097436

Updated information and services can be found at:

<http://bjo.bmj.com/content/90/8/1060.full.html>

These include:

References

This article cites 168 articles, 76 of which can be accessed free at:

<http://bjo.bmj.com/content/90/8/1060.full.html#ref-list-1>

Article cited in:

<http://bjo.bmj.com/content/90/8/1060.full.html#related-urls>

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections

Articles on similar topics can be found in the following collections

[Retina](#) (1207 articles)

[Eye \(globe\)](#) (538 articles)

Notes

To request permissions go to:

<http://group.bmj.com/group/rights-licensing/permissions>

To order reprints go to:

<http://journals.bmj.com/cgi/reprintform>

To subscribe to BMJ go to:

<http://group.bmj.com/subscribe/>